Department of Clinical Pharmacology, Aalborg University Hospital, Gartnerboligen, ground floor Mølleparkvej 8a, 9000, Aalborg, Denmark.
Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Int J Clin Pharm. 2021 Apr;43(2):351-357. doi: 10.1007/s11096-020-01057-6. Epub 2020 May 19.
Background Transdermal opioids are widely used among elderly adults with chronic pain. However, transdermal patches may be involved in a significant proportion of opioid-related patient safety incidents, as the application process includes several subprocesses, each associated with an individual risk of error. Objective The aim was to obtain specific knowledge on patient safety incidents related to transdermal opioid treatment within both the primary care sector and the hospital sector in Denmark. Setting The study is descriptive with data provided by the Danish Patient Safety Database. Methods We manually retrieved all patient safety incidents concerning transdermal opioids reported for 2018 from (1) the hospital sector and (2) the primary care sector. Study data were collected and managed using REDCap electronic data capture tools. Main outcome measure The available information for each incident was sorted into the following categories: location, medication process, type of problem, outcome at time of reporting, and outcome classification. Results A total of 866 patient safety incidents involving transdermal opioids were reported to the Danish Patient Safety Database in 2018. No fatal incidents were present in the database. In 386 cases, the incidents were reported as harmful, and these 386 cases were analysed. Most reports came from the primary care sector (nursing home, home care or social housing). The majority of incidents were related to the administration of the patch in the medication process, and the most prevalent problem was the omission of doses. Conclusion This study has demonstrated that the administration of transdermal opioids is challenging and may cause harm, particularly in the primary care sector. To improve patient safety, optimized systems, including guidelines on drug management and the continuing education of healthcare personnel in transdermal opioid management, are necessary. These guidelines should preferably incorporate reminders and checklists, since the omission of doses was the most reported problem.
背景 透皮阿片类药物在慢性疼痛的老年患者中广泛使用。然而,透皮贴剂可能涉及到相当大比例的阿片类药物相关的患者安全事件,因为应用过程包括几个子过程,每个子过程都存在单独的错误风险。目的 旨在获得丹麦初级保健和医院部门中与透皮阿片类药物治疗相关的患者安全事件的具体知识。设置 本研究是描述性的,数据来自丹麦患者安全数据库。方法 我们从(1)医院部门和(2)初级保健部门手动检索了 2018 年报告的所有与透皮阿片类药物相关的患者安全事件。研究数据使用 REDCap 电子数据捕获工具进行收集和管理。主要结果 2018 年,丹麦患者安全数据库共报告了 866 例涉及透皮阿片类药物的患者安全事件。数据库中没有致命事件。在 386 例报告中,事件被报告为有害,对这 386 例进行了分析。大多数报告来自初级保健部门(疗养院、家庭护理或社会住房)。大多数事件与药物治疗过程中的贴剂给药有关,最常见的问题是剂量遗漏。结论 本研究表明,透皮阿片类药物的给药具有挑战性,可能会造成伤害,尤其是在初级保健部门。为了提高患者安全性,需要优化系统,包括药物管理指南和医疗保健人员在透皮阿片类药物管理方面的继续教育,这些指南最好纳入提醒和检查表,因为剂量遗漏是最常见的问题。